Use of conventional synthetic and biologic disease-modifying anti-rheumatic drugs in patients with rheumatic diseases contracting COVID-19: a single-center experience

To examine whether patients with inflammatory arthritis (IA) treated with conventional synthetic (cs) disease-modifying anti-rheumatic drugs (DMARDs) and/or biologic (b) DMARDs, could be affected from SARS-CoV-2 infection and to explore the COVID-19 disease course and outcome in this population. Thi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Rheumatol Int
Main Authors: Migkos, Michalis P., Kaltsonoudis, Evripidis, Pelechas, Eleftherios, Drossou, Vassiliki, Karagianni, Panagiota G., Kavvadias, Athanasios, Voulgari, Paraskevi V., Drosos, Alexandros A.
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2021
Assuntos:
Observational Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7925256/
https://ncbi.nlm.nih.gov/pubmed/33655421
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00296-021-04818-2
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados